Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy. [2] Sparsentan is an endothelin and angiotensin II receptor antagonist. [2] [5] It is taken by mouth. [2]

WHAT IS FILSPARI ® (sparsentan)? FILSPARI is a prescription medicine used to slow kidney function decline in adults with a kidney disease called primary IgA nephropathy (IgAN), who are at risk for their disease getting worse.

Aug 22, 2023 · Sparsentan is used to lower levels of protein in the urine (proteinuria) in adults with a kidney disease called primary immunoglobulin A nephropathy. Sparsentan is available only from a certified pharmacy under a special program. You must be registered in the program and understand the risks and benefits of sparsentan.

Learn about FILSPARI® (sparsentan), a prescription treatment for adults with primary IgA nephropathy. See safety info.

May 5, 2023 · Sparsentan is a new drug approved by the FDA in February, 2023, to reduce protein excretion in urine (proteinuria) in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.

Mar 1, 2025 · Sparsentan is used to slow kidney function decline in patients who have a kidney disease called primary immunoglobulin A nephropathy (IgAN), who are at risk of their disease worsening quickly. This medicine is available only under a restricted distribution program called Filspari® REMS (Risk Evaluation and Mitigation Strategy) Program.

Filspari (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.

WHAT IS FILSPARI ® (sparsentan)? FILSPARI is a prescription medicine used to slow kidney function decline in adults with a kidney disease called primary IgA nephropathy (IgAN), who are at risk for their disease getting worse. It is not known if FILSPARI is safe and effective in children.

Indicated to slow kidney function decline in adults with primaryimmunoglobulin A nephropathy (IgAN) who are at risk for disease progression. 200 mg PO qDay initially; after 14 days, increase...

Sparsentan is in a class of medications called endothelin and angiotensin II receptor antagonists. It works by blocking two substances, endothelin and angiotensin II, that play a role in the progression of kidney disease.